Agenus Inc. (NASDAQ:AGEN) was down 1.3% on Monday . The company traded as low as $6.12 and last traded at $6.14, with a volume of 1,180,931 shares changing hands. The stock had previously closed at $6.22.

A number of equities research analysts have recently weighed in on AGEN shares. Maxim Group reissued a “buy” rating on shares of Agenus in a research note on Wednesday, April 27th. HC Wainwright restated a “buy” rating on shares of Agenus in a report on Saturday, April 30th. Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Finally, Jefferies Group boosted their price target on Agenus from $6.00 to $7.00 and gave the company a “buy” rating in a report on Friday, July 29th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $10.25.

The stock’s 50-day moving average price is $5.03 and its 200 day moving average price is $4.06. The firm’s market cap is $533.64 million.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, July 28th. The company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.01. The firm had revenue of $6.59 million for the quarter, compared to analysts’ expectations of $5.12 million. Analysts forecast that Agenus Inc. will post ($1.27) earnings per share for the current year.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.